KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Identifieur interne : 009E40 ( Main/Exploration ); précédent : 009E39; suivant : 009E41KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Auteurs : Maria Debiec-Rychter [Belgique] ; Raf Sciot [Belgique] ; Axel Le Cesne [France] ; Marcus Schlemmer [Allemagne] ; Peter Hohenberger [Allemagne] ; Allan T. Van Oosterom [Belgique] ; Jean-Yves Blay [France] ; Serge Leyuraz [Suisse] ; Michel Stul [Belgique] ; Paolo G. Casali [Italie] ; John Zalcberg [Australie] ; Jaap Verweij ; Martine Van Glabbeke [Belgique] ; Anne Hagemeijer [Belgique] ; Ian Judson [Royaume-Uni]Source :
- European journal of cancer : (1990) [ 0959-8049 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme, Pharmacologie.
English descriptors
- KwdEn :
Abstract
A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with advanced gastrointestinal stromal tumours (GISTs), reported dose dependency for progression-free survival. The current analysis of that study aimed to assess if tumour mutational status correlates with clinical response to imatinib. Pre-treatment samples of GISTs from 377 patients enrolled in phase III study were analyzed for mutations of KIT or PDGFRA by combination of D-HPLC and direct sequencing of tumour genomic DNA. Mutation types were correlated with patients' survival data. The presence of exon 9-activating mutations in KIT was the strongest adverse prognostic factor for response to imatinib, increasing the relative risk of progression by 171% (P < 0.0001) and the relative risk of death by 190% (P < 0.0001) when compared with KIT exon 11 mutants. Similarly, the relative risk of progression was increased by 108% (P < 0.0001) and the relative risk of death by 76% (P=0.028) in patients without detectable KIT or PDGFRA mutations. In patients whose tumours expressed an exon 9 KIT oncoprotein, treatment with the high-dose regimen resulted in a significantly superior progression-free survival (P= 0.0013), with a reduction of the relative risk of 61%. We conclude that tumour genotype is of major prognostic significance for progression-free survival and overall survival in patients treated with imatinib for advanced GISTs. Our findings suggest the need for differential treatment of patients with GISTs, with KIT exon 9 mutant patients benefiting the most from the 800 mg daily dose of the drug.
Affiliations:
- Allemagne, Australie, Belgique, France, Italie, Royaume-Uni, Suisse
- Angleterre, Auvergne-Rhône-Alpes, Bavière, Berlin, Canton de Vaud, District de Haute-Bavière, Grand Londres, Province du Brabant flamand, Rhône-Alpes, Région de Bruxelles-Capitale, Victoria (État)
- Berlin, Bruxelles, Lausanne, Londres, Louvain, Lyon, Melbourne, Munich
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 004387
- to stream PascalFrancis, to step Curation: 001D08
- to stream PascalFrancis, to step Checkpoint: 003F27
- to stream Main, to step Merge: 00A949
- to stream Main, to step Curation: 009E40
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours</title><author><name sortKey="Debiec Rychter, Maria" sort="Debiec Rychter, Maria" uniqKey="Debiec Rychter M" first="Maria" last="Debiec-Rychter">Maria Debiec-Rychter</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Human Genetics, University of Leuuen and University Hospital Gasthuisberg, O&N Gasthuisberg, Herestraat 49</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Sciot, Raf" sort="Sciot, Raf" uniqKey="Sciot R" first="Raf" last="Sciot">Raf Sciot</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Pathology, University of Leuuen and University Hospital Gasthuisberg, Herestraat 49</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>2 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Le Cesne, Axel" sort="Le Cesne, Axel" uniqKey="Le Cesne A" first="Axel" last="Le Cesne">Axel Le Cesne</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut Gustave Roussy</s1><s2>Villejuif</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Institut Gustave Roussy</wicri:noRegion><wicri:noRegion>Institut Gustave Roussy</wicri:noRegion></affiliation></author><author><name sortKey="Schlemmer, Marcus" sort="Schlemmer, Marcus" uniqKey="Schlemmer M" first="Marcus" last="Schlemmer">Marcus Schlemmer</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Medical Oncology, Klinikum Grosshadern</s1><s2>Munich</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>GSF - National Research Center for Environment and Health</s1><s2>Neuherberg</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Neuherberg</wicri:noRegion><wicri:noRegion>GSF - National Research Center for Environment and Health</wicri:noRegion><wicri:noRegion>GSF - National Research Center for Environment and Health</wicri:noRegion></affiliation></author><author><name sortKey="Hohenberger, Peter" sort="Hohenberger, Peter" uniqKey="Hohenberger P" first="Peter" last="Hohenberger">Peter Hohenberger</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Charité, Robert Roessle Klinik</s1><s2>Berlin</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Van Oosterom, Allan T" sort="Van Oosterom, Allan T" uniqKey="Van Oosterom A" first="Allan T." last="Van Oosterom">Allan T. Van Oosterom</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Medical Oncology, University of Leuven and University Hospital Gasthuisberg, Herestraat 49</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Centre Leon Berard</s1><s2>Lyon</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Leyuraz, Serge" sort="Leyuraz, Serge" uniqKey="Leyuraz S" first="Serge" last="Leyuraz">Serge Leyuraz</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>CHU Vaudois</s1><s2>Lausanne</s2><s3>CHE</s3><sZ>8 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Stul, Michel" sort="Stul, Michel" uniqKey="Stul M" first="Michel" last="Stul">Michel Stul</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Human Genetics, University of Leuuen and University Hospital Gasthuisberg, O&N Gasthuisberg, Herestraat 49</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Casali, Paolo G" sort="Casali, Paolo G" uniqKey="Casali P" first="Paolo G." last="Casali">Paolo G. Casali</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Instituto Nazionale Tumori</s1><s2>Milano</s2><s3>ITA</s3><sZ>10 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Instituto Nazionale Tumori</wicri:noRegion></affiliation></author><author><name sortKey="Zalcberg, John" sort="Zalcberg, John" uniqKey="Zalcberg J" first="John" last="Zalcberg">John Zalcberg</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Peter MacCallum Cancer Centre</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>11 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Verweij, Jaap" sort="Verweij, Jaap" uniqKey="Verweij J" first="Jaap" last="Verweij">Jaap Verweij</name></author><author><name sortKey="Van Glabbeke, Martine" sort="Van Glabbeke, Martine" uniqKey="Van Glabbeke M" first="Martine" last="Van Glabbeke">Martine Van Glabbeke</name><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>EORTC Data Center</s1><s2>Brussels</s2><s3>BEL</s3><sZ>13 aut.</sZ></inist:fA14><country>Belgique</country><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Hagemeijer, Anne" sort="Hagemeijer, Anne" uniqKey="Hagemeijer A" first="Anne" last="Hagemeijer">Anne Hagemeijer</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Human Genetics, University of Leuuen and University Hospital Gasthuisberg, O&N Gasthuisberg, Herestraat 49</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Judson, Ian" sort="Judson, Ian" uniqKey="Judson I" first="Ian" last="Judson">Ian Judson</name><affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0282946</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0282946 INIST</idno><idno type="RBID">Pascal:06-0282946</idno><idno type="wicri:Area/PascalFrancis/Corpus">004387</idno><idno type="wicri:Area/PascalFrancis/Curation">001D08</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003F27</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003F27</idno><idno type="wicri:doubleKey">0959-8049:2006:Debiec Rychter M:kit:mutations:and</idno><idno type="wicri:Area/Main/Merge">00A949</idno><idno type="wicri:Area/Main/Curation">009E40</idno><idno type="wicri:Area/Main/Exploration">009E40</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours</title><author><name sortKey="Debiec Rychter, Maria" sort="Debiec Rychter, Maria" uniqKey="Debiec Rychter M" first="Maria" last="Debiec-Rychter">Maria Debiec-Rychter</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Human Genetics, University of Leuuen and University Hospital Gasthuisberg, O&N Gasthuisberg, Herestraat 49</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Sciot, Raf" sort="Sciot, Raf" uniqKey="Sciot R" first="Raf" last="Sciot">Raf Sciot</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Pathology, University of Leuuen and University Hospital Gasthuisberg, Herestraat 49</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>2 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Le Cesne, Axel" sort="Le Cesne, Axel" uniqKey="Le Cesne A" first="Axel" last="Le Cesne">Axel Le Cesne</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut Gustave Roussy</s1><s2>Villejuif</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Institut Gustave Roussy</wicri:noRegion><wicri:noRegion>Institut Gustave Roussy</wicri:noRegion></affiliation></author><author><name sortKey="Schlemmer, Marcus" sort="Schlemmer, Marcus" uniqKey="Schlemmer M" first="Marcus" last="Schlemmer">Marcus Schlemmer</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Medical Oncology, Klinikum Grosshadern</s1><s2>Munich</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>GSF - National Research Center for Environment and Health</s1><s2>Neuherberg</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Neuherberg</wicri:noRegion><wicri:noRegion>GSF - National Research Center for Environment and Health</wicri:noRegion><wicri:noRegion>GSF - National Research Center for Environment and Health</wicri:noRegion></affiliation></author><author><name sortKey="Hohenberger, Peter" sort="Hohenberger, Peter" uniqKey="Hohenberger P" first="Peter" last="Hohenberger">Peter Hohenberger</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Charité, Robert Roessle Klinik</s1><s2>Berlin</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Van Oosterom, Allan T" sort="Van Oosterom, Allan T" uniqKey="Van Oosterom A" first="Allan T." last="Van Oosterom">Allan T. Van Oosterom</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Medical Oncology, University of Leuven and University Hospital Gasthuisberg, Herestraat 49</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Centre Leon Berard</s1><s2>Lyon</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Leyuraz, Serge" sort="Leyuraz, Serge" uniqKey="Leyuraz S" first="Serge" last="Leyuraz">Serge Leyuraz</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>CHU Vaudois</s1><s2>Lausanne</s2><s3>CHE</s3><sZ>8 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Stul, Michel" sort="Stul, Michel" uniqKey="Stul M" first="Michel" last="Stul">Michel Stul</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Human Genetics, University of Leuuen and University Hospital Gasthuisberg, O&N Gasthuisberg, Herestraat 49</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Casali, Paolo G" sort="Casali, Paolo G" uniqKey="Casali P" first="Paolo G." last="Casali">Paolo G. Casali</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Instituto Nazionale Tumori</s1><s2>Milano</s2><s3>ITA</s3><sZ>10 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Instituto Nazionale Tumori</wicri:noRegion></affiliation></author><author><name sortKey="Zalcberg, John" sort="Zalcberg, John" uniqKey="Zalcberg J" first="John" last="Zalcberg">John Zalcberg</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Peter MacCallum Cancer Centre</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>11 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Verweij, Jaap" sort="Verweij, Jaap" uniqKey="Verweij J" first="Jaap" last="Verweij">Jaap Verweij</name></author><author><name sortKey="Van Glabbeke, Martine" sort="Van Glabbeke, Martine" uniqKey="Van Glabbeke M" first="Martine" last="Van Glabbeke">Martine Van Glabbeke</name><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>EORTC Data Center</s1><s2>Brussels</s2><s3>BEL</s3><sZ>13 aut.</sZ></inist:fA14><country>Belgique</country><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Hagemeijer, Anne" sort="Hagemeijer, Anne" uniqKey="Hagemeijer A" first="Anne" last="Hagemeijer">Anne Hagemeijer</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Human Genetics, University of Leuuen and University Hospital Gasthuisberg, O&N Gasthuisberg, Herestraat 49</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Judson, Ian" sort="Judson, Ian" uniqKey="Judson I" first="Ian" last="Judson">Ian Judson</name><affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>15 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j" type="main">European journal of cancer : (1990)</title><title level="j" type="abbreviated">Eur. j. cancer : (1990)</title><idno type="ISSN">0959-8049</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">European journal of cancer : (1990)</title><title level="j" type="abbreviated">Eur. j. cancer : (1990)</title><idno type="ISSN">0959-8049</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>Antineoplastic agent</term><term>Cancerology</term><term>Dose</term><term>Enzyme inhibitor</term><term>Gastrointestinal stromal tumor</term><term>Human</term><term>Imatinib</term><term>Mutation</term><term>Pharmacology</term><term>Protein-tyrosine kinase</term><term>Selection</term><term>kit Gene</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Imatinib</term><term>Mutation</term><term>Gène kit</term><term>Dose</term><term>Sélection</term><term>Protein-tyrosine kinase</term><term>Inhibiteur enzyme</term><term>Homme</term><term>Stade avancé</term><term>Cancérologie</term><term>Pharmacologie</term><term>Anticancéreux</term><term>Tumeur stromale gastrointestinale</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Pharmacologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with advanced gastrointestinal stromal tumours (GISTs), reported dose dependency for progression-free survival. The current analysis of that study aimed to assess if tumour mutational status correlates with clinical response to imatinib. Pre-treatment samples of GISTs from 377 patients enrolled in phase III study were analyzed for mutations of KIT or PDGFRA by combination of D-HPLC and direct sequencing of tumour genomic DNA. Mutation types were correlated with patients' survival data. The presence of exon 9-activating mutations in KIT was the strongest adverse prognostic factor for response to imatinib, increasing the relative risk of progression by 171% (P < 0.0001) and the relative risk of death by 190% (P < 0.0001) when compared with KIT exon 11 mutants. Similarly, the relative risk of progression was increased by 108% (P < 0.0001) and the relative risk of death by 76% (P=0.028) in patients without detectable KIT or PDGFRA mutations. In patients whose tumours expressed an exon 9 KIT oncoprotein, treatment with the high-dose regimen resulted in a significantly superior progression-free survival (P= 0.0013), with a reduction of the relative risk of 61%. We conclude that tumour genotype is of major prognostic significance for progression-free survival and overall survival in patients treated with imatinib for advanced GISTs. Our findings suggest the need for differential treatment of patients with GISTs, with KIT exon 9 mutant patients benefiting the most from the 800 mg daily dose of the drug.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>Suisse</li></country><region><li>Angleterre</li><li>Auvergne-Rhône-Alpes</li><li>Bavière</li><li>Berlin</li><li>Canton de Vaud</li><li>District de Haute-Bavière</li><li>Grand Londres</li><li>Province du Brabant flamand</li><li>Rhône-Alpes</li><li>Région de Bruxelles-Capitale</li><li>Victoria (État)</li></region><settlement><li>Berlin</li><li>Bruxelles</li><li>Lausanne</li><li>Londres</li><li>Louvain</li><li>Lyon</li><li>Melbourne</li><li>Munich</li></settlement></list><tree><noCountry><name sortKey="Verweij, Jaap" sort="Verweij, Jaap" uniqKey="Verweij J" first="Jaap" last="Verweij">Jaap Verweij</name></noCountry><country name="Belgique"><region name="Province du Brabant flamand"><name sortKey="Debiec Rychter, Maria" sort="Debiec Rychter, Maria" uniqKey="Debiec Rychter M" first="Maria" last="Debiec-Rychter">Maria Debiec-Rychter</name></region><name sortKey="Hagemeijer, Anne" sort="Hagemeijer, Anne" uniqKey="Hagemeijer A" first="Anne" last="Hagemeijer">Anne Hagemeijer</name><name sortKey="Sciot, Raf" sort="Sciot, Raf" uniqKey="Sciot R" first="Raf" last="Sciot">Raf Sciot</name><name sortKey="Stul, Michel" sort="Stul, Michel" uniqKey="Stul M" first="Michel" last="Stul">Michel Stul</name><name sortKey="Van Glabbeke, Martine" sort="Van Glabbeke, Martine" uniqKey="Van Glabbeke M" first="Martine" last="Van Glabbeke">Martine Van Glabbeke</name><name sortKey="Van Oosterom, Allan T" sort="Van Oosterom, Allan T" uniqKey="Van Oosterom A" first="Allan T." last="Van Oosterom">Allan T. Van Oosterom</name></country><country name="France"><noRegion><name sortKey="Le Cesne, Axel" sort="Le Cesne, Axel" uniqKey="Le Cesne A" first="Axel" last="Le Cesne">Axel Le Cesne</name></noRegion><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name></country><country name="Allemagne"><region name="Bavière"><name sortKey="Schlemmer, Marcus" sort="Schlemmer, Marcus" uniqKey="Schlemmer M" first="Marcus" last="Schlemmer">Marcus Schlemmer</name></region><name sortKey="Hohenberger, Peter" sort="Hohenberger, Peter" uniqKey="Hohenberger P" first="Peter" last="Hohenberger">Peter Hohenberger</name><name sortKey="Schlemmer, Marcus" sort="Schlemmer, Marcus" uniqKey="Schlemmer M" first="Marcus" last="Schlemmer">Marcus Schlemmer</name></country><country name="Suisse"><region name="Canton de Vaud"><name sortKey="Leyuraz, Serge" sort="Leyuraz, Serge" uniqKey="Leyuraz S" first="Serge" last="Leyuraz">Serge Leyuraz</name></region></country><country name="Italie"><noRegion><name sortKey="Casali, Paolo G" sort="Casali, Paolo G" uniqKey="Casali P" first="Paolo G." last="Casali">Paolo G. Casali</name></noRegion></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Zalcberg, John" sort="Zalcberg, John" uniqKey="Zalcberg J" first="John" last="Zalcberg">John Zalcberg</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Judson, Ian" sort="Judson, Ian" uniqKey="Judson I" first="Ian" last="Judson">Ian Judson</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009E40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009E40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:06-0282946
|texte= KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
}}
| This area was generated with Dilib version V0.6.33. |  |